Fundraising FoxOlive Tree Capital — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Arva provides financial crime compliance software for compliance teams in financial services, helping them work more efficiently on detection and monitoring tasks.
AI & Machine LearningEnterprise SoftwareFintechNew York City, US
Rhim Shah(CEO)inOli Wales(CTO)inSohum Shah(Chief of Staff)Dajana Marsollek(CRO)Renato Angrisani(Head of Product)Hardik Sangwan(Software Engineer)
Co-investorsY CombinatorGradient Ventures468 CapitalAmino CapitalOakNorthOxford Seed Fund+2 more
-2.png)
Orbital Ops develops propulsion systems and related aerospace hardware for airborne vehicles.
Advanced ManufacturingDeep TechDefense TechHardwareSpace TechLos Angeles, US
Ben Schleuniger(CEO)inRoss Doherty(COO)inHunterNico Montoya(Founding Engineer)
Co-investorsAlumni VenturesBlack FlagGaingelsGoAhead VenturesInitialized CapitalMaiora Rebel Ventures+16 more
__Twitter.png)
Propolis provides automated quality assurance testing using multiple autonomous browser agents that simulate user behavior on websites and applications.
Enterprise SoftwareNew York City, US
Marc Papazian(CEO)inMatt White(CTO)inFabien Claude Garic(Executive Officer)
Co-investorsY CombinatorAndreessen HorowitzNexus Venture PartnersPeak XV PartnersSAV (Scale Asia Ventures)Sequoia Capital+1 more
Pulse is a document intelligence platform that uses OCR, layout analysis, and vision models to extract structured data from complex documents for enterprise and AI teams.
AI & Machine LearningData & InfrastructureEnterprise SoftwareSan Francisco, US
Sid Manchkanti(CEO)inRitvik Pandey(CTO)inAnand Thaker(Founder)inChaitu Aluru(Founder)inMayank Mehta(Founder)inRaj Singh(Founder)
Co-investorsVocal VenturesY CombinatorAmplify.LAAntlerCEOs'Crosslink Capital+6 more
Rinascera Therapeutics develops treatments for rare genetic skin diseases, with drug candidates targeting conditions such as Gorlin Syndrome and Dystrophic Epidermolysis Bullosa.
BiotechHealthtechBoston, US
Nichola Eliovits(Executive Officer, Director)Max Dawson(Executive Officer)inKarl Beutner(Executive Officer, Director)
BoardDaniel Yadegar(Director)
Co-investorsNewpath Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.